Xeris Biopharma (NASDAQ:XERS) Stock Gets Price Target Boost from HC Wainwright

Xeris Biopharma (NASDAQ:XERS) had its target price hoisted by equities researchers at HC Wainwright from $10.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 37.61% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays increased their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Finally, Leerink Partners lifted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.80.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $13.08 on Friday. Xeris Biopharma has a fifty-two week low of $5.25 and a fifty-two week high of $13.74. The business has a 50-day moving average of $9.49 and a two-hundred day moving average of $7.58. The stock has a market capitalization of $2.38 billion, a P/E ratio of -118.91 and a beta of 0.61. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, equities research analysts predict that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Kevin McCulloch sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the sale, the insider directly owned 1,614,208 shares of the company’s stock, valued at approximately $16,142,080. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of Xeris Biopharma stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the transaction, the insider owned 1,086,130 shares in the company, valued at $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 148,332 shares of company stock valued at $1,409,221 in the last quarter. Insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Vilga Financial Planning LLC acquired a new stake in Xeris Biopharma in the 3rd quarter valued at approximately $10,134,000. Legal & General Group Plc bought a new position in Xeris Biopharma in the 2nd quarter worth approximately $15,941,000. Walleye Capital LLC acquired a new position in shares of Xeris Biopharma during the second quarter worth approximately $4,841,000. Canada Pension Plan Investment Board acquired a new position in shares of Xeris Biopharma during the second quarter worth approximately $1,736,000. Finally, Bank of America Corp DE acquired a new position in shares of Xeris Biopharma during the second quarter worth approximately $11,065,000. Institutional investors own 42.75% of the company’s stock.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results topped estimates: Xeris reported earnings of $0.06 per share versus the approximately $0.03 consensus, and revenue of $107.23 million versus estimates of $101.68 million. Earnings also improved from break-even a year earlier. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Long-term commercial potential: CEO John Shannon said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected. Xeris also updated its FY2030 earnings guidance; the provided report does not specify the revised figures. Xeris CEO sees Recorlev nearing $1B in annual sales
• Negative Sentiment: Insider selling: Three insiders sold a combined 45,000 shares at $10.23 each. The sales were conducted under pre-arranged Rule 10b5-1 plans, and the sellers retained substantial holdings, which may temper the signal. Xeris Biopharma insider share sale

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.